CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2021; 42(04): 353-355
DOI: 10.1055/s-0041-1735440
Trainees’ Corner

The Cancer Genome Atlas

B. Minu Chandra Muddabhaktuni
1   Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, Ahmedabad, Gujarat, India
Venkata Pradeep Babu Koyyala
1   Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, Ahmedabad, Gujarat, India
› Author Affiliations

What Is the Cancer Genome Atlas–Origin?

The Cancer Genome Atlas (TCGA) is a landmark cancer genomics program started in 2006 to molecularly characterize different types of cancers. This was a joint effort of the US government-funded National Cancer Institute and National Human Genome Research Institute under the guidance of Dr. Jean Claude Zenklusen.[1]

Publication History

Article published online:
25 November 2021

© 2021. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

  • References

  • 1 The Cancer Genome Atlas-Timeline and Milestones. National Cancer Institute; 2020. Available from: Accessed July 19, 2021.
  • 2 Brat DJ, Verhaak RG, Aldape KD. et al Cancer Genome Atlas Research Network. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 2015; 372 (26) 2481-2498
  • 3 Soslow RA, Tornos C, Park KJ. et al Endometrial carcinoma diagnosis: Use of FIGO grading and genomic subcategories in clinical practice: recommendations of the international society of gynecological pathologists. Int J Gynecol Pathol 2019; 38 (Suppl. 01) S64-S74
  • 4 Creutzberg CL, Leon-Castillo A, De Boer SM. et al LBA63 molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: Impact on adjuvant therapy. Ann Oncol 2019; 30 (Suppl. 05) mdz394-mdz060
  • 5 Cancer Genome Atlas Research Network. Albert Einstein College of Medicine, Analytical Biological Services, Barretos Cancer Hospital, Baylor College of Medicine, Beckman Research Institute of City of Hope, et al Integrated genomic and molecular characterization of cervical cancer. Nature 2017; 543: 378-384